Company intelligence / Profile preview

Amira Pharmaceuticals

San Diego, California, United Statesamirapharm.com ↗

Ownership: Private
Employees: ~16
Development stage: Other

Overview

Amira Pharmaceuticals developed small molecule drugs targeting inflammatory and fibrotic diseases. Its lead compound, AM152, an LPA1 antagonist for IPF and SSc, completed Phase I with encouraging results. The company also advanced FLAP inhibitors in partnership with GSK for respiratory/cardiovascular disease. Upon acquisition by Bristol Myers Squibb in September 2011, the pipeline included several early-stage assets focused on bioactive lipid pathways.

Therapeutic areas: PulmonologyImmunologyRheumatologyCardiovascularNeurology
Modalities: Small molecules
Industry: Biotech

Partnerships

GlaxoSmithKline – partnership on FLAP inhibitors for respiratory/cardiovascular disease ($425M potential deal value).

Beyond the preview

Go deeper on Amira Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amira Pharmaceuticals.